EUVIMEDEUVIMED entdecken
Crossref

Early Treatment-Resistance in First Episode Psychosis

Piyumi Fernando, Johanna Strauss, Elias Wagner, Lisa Löhrs, Mattia Campana, Peter Falkai, Alkomiet Hasan, Irina Papazova

Pharmacopsychiatry · 01.03.2025 · 58 (02) · 63-70

DOI: 10.1055/a-2421-2411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.03.2025. Verfasst von Piyumi Fernando und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, Bezirkskrankenhaus Schwaben, Universitätsklinikum Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Antipsychotic Agents, Psychotic Disorders, Clozapine, Schizophrenia, Treatment-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Approximately 30% of individuals with schizophrenia experience treatment resistance (TR), with 70% exhibiting it from the onset. Most research fails to distinguish between acquired and innate resistance, with limited data on TR in first episode psychosis (FEP). However, FEP patients with TR experience progressively worse outcomes compared to those with initial response. To further understand these findings, clinical and demographic data of FEP patients with and without TR were compared in this naturalistic study.

Methods

Information was extracted on FEP patients who were antipsychotic-naive at the time of admission from a retrospective database on F2x diagnosed patients admitted to the LMU psychiatric clinic between 2008 and 2018. Clozapine was used at discharge as a marker of TR in the FEP cohort. A similarly antipsychotic-naïve FEP control group without clozapine at discharge, was generated by matching for gender and age. Thirty clinical and demographic variables were analyzed to identify differences.

Results

Two-hundred forty antipsychotic-naive FEPs were included: 33 with clozapine at discharge (TRC group), and 207 in the control group (non-TRC). Significant differences were observed in inpatient stay duration, chlorpromazine-equivalent dosage, number of antipsychotics, and anticholinergic medication at discharge.

Discussion

The findings indicate that longer inpatient stay, an increased number of antipsychotics, and possibly a more extended prodrome may serve as markers for non-clozapine TR in FEP. Further research is necessary to establish the robustness of these variables as early-stage TR markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsPsychotic DisordersClozapineSchizophrenia, Treatment-ResistantSchizophreniaDrug ResistanceHumansMaleFemaleAdultRetrospective StudiesYoung AdultAdolescentLength of Stay

Substanzen

Antipsychotic AgentsClozapine

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, Bezirkskrankenhaus Schwaben, Universitätsklinikum Augsburg, Augsburg, Germany.
  • Department of Psychiatry and Psychotherapy, Klinikum der Universität München, Ludwig Maximilians University, München, Germany.
  • DZPG (German Center for Mental Health), partner site München/Augsburg, Germany.

Zitieren

APA

Fernando, P., Strauss, J., Wagner, E., Löhrs, L., Campana, M., Falkai, P., Hasan, A., & Papazova, I. (2025). Early Treatment-Resistance in First Episode Psychosis. Pharmacopsychiatry, 58(02), 63-70. https://doi.org/10.1055/a-2421-2411

Vancouver

Fernando P, Strauss J, Wagner E, Löhrs L, Campana M, Falkai P, et al. Early Treatment-Resistance in First Episode Psychosis. Pharmacopsychiatry. 2025;58(02):63-70. doi:10.1055/a-2421-2411

BibTeX
@article{Fernando2025,
  author = {Fernando, Piyumi and Strauss, Johanna and Wagner, Elias and Löhrs, Lisa and Campana, Mattia and Falkai, Peter and Hasan, Alkomiet and Papazova, Irina},
  title = {Early Treatment-Resistance in First Episode Psychosis},
  journal = {Pharmacopsychiatry},
  year = {2025},
  volume = {58},
  number = {02},
  pages = {63--70},
  doi = {10.1055/a-2421-2411}
}
Kostenlos starten →